ABSTRACT Platelets produce a range of bronchoconstrictor mediators. Measurements of plasma factors have implicated platelet activation in allergic asthma, and sensitised guineapigs challenged with ovalbumin show pulmonary platelet aggregation accompanying bronchoconstriction. To investigate this further we injected autologous platelets labelled with indium 111 and red cells labelled with technetium 99m into three young volunteers with atopic asthma and three nonasthmatic volunteers and, after equilibration of platelets between blood and splenic pool, monitored lung 99mTc and "I'In activities continuously. Comparison with the corresponding activities in blood samples allowed calculation of pulmonary platelet to red cell transit time ratio (tp/tr). This ratio was 0.9, 1.02, and 0.98 in the non-asthmatic subjects compared with 1.04, 0.97, and 1.17 in the asthmatic subjects. This argues against the existence of an intrapulmonary platelet pool in normal subjects; transpulmonary transit time was slightly prolonged in one asthmatic subject. Bronchial challenge with Dermatophagoides pteronyssinus was performed in the asthmatic subjects and monitoring continued for a further 30 minutes. Antigen induced falls in FEV, of 20-50% were accompanied by small decreases in the "I' In but not in the 99mTc lung signal. In line with this k/er fell to 0.89, 0.89, and 1.05. Antigen induced bronchoconstriction was therefore not accompanied by intrapulmonary platelet accumulation. Platelet survival was normal at 10.2 days in both groups of subjects.
Platelets produce many potent bronchoconstrictor mediators, including thromboxanes,' cyclic endoperoxides,2 slow reacting substance,3 5-hydroxytryptamine,4 and histamine.5 Platelet activating factor is released by IgE mediated activation of basophils and alveolar macrophages. 6 Platelet activating factor contracts smooth muscle by a direct action and produces platelet dependent bronchoconstriction in guineapigs7 and baboons.8 In man platelet activation has been implicated in asthma by the demonstration of increased blood levels of platelet factor 4 (PF4)9 and 13 thromboglobulin"' 10 minutes after antigen induced bronchoconstriction. Platelet accumulation has been demonstrated in the lungs of sensitised guineapigs challenged with antigen.'2 To evaluate the relevance of this observation to human asthma we have monitored lung radioactivity continuously in asthmatic subjects, previously injected with autologous platelets labelled with indium 111," before, during, and after antigen bronchial provocation. Because changes in pulmonary platelet numbers may be obscured by changes in blood volume induced by bronchoconstriction we have also measured pulmonary platelet transit time relative to red cell transit time using technetium 99m. This transit time ratio has been compared in asthmatic and normal subjects, and before and after bronchial provocation in those with asthma.
Methods

SUBJECTS
Six subjects were studied-three normal volunteers and three asthmatic patients. Salient Without interruption of dynamic imaging, labelled platelets were injected after the spectrum had been adjusted to the upper of the two "'In photopeaks (247 Kev). Blood sampling was continued at intervals up to the termination of the dynamic imaging sequence, which was 90-120 minutes in the three asthmatic subjects and 40-50 minutes in the normal subjects. The counting window was recentred over the 99mTc photopeak at intervals after injection of platelets. Cell bound radioactivity was calculated from the packed cell volume after the activities of 1 ml aliquots of whole blood and cell free plasma had been counted in a gamma well counter. "Cross talk" between "I' In and 99mTc was corrected for. Blood sampling was continued at intervals over the next seven days for calculation of platelet lifespan.
ANTIGEN CHALLENGE
This was performed in the three asthmatic subjects during continuous gamma camera monitoring after the reinjected labelled platelets had equilibrated between circulating blood and the splenic platelet pool-that is, after the chest, splenic, and hepatic activity signals had become constant. The concentration of antigen (D pteronyssinus, Pharmacia) used on the study day was determined one to two weeks beforehand as follows. After initial measurements of forced expiratory volume in one second (FEV,), vital capacity (VC), and peak expiratory flow rate (PEFR), (the best of three attempts being taken) made with a Vitalograph spirometer and Wright peak flow meter, the asthmatic subjects inhaled an albumin carrier solution for two minutes from a Wright's nebuliser (output 0.13 ml min-'). Measurements of FEV1 and PEFR were repeated immediately afterwards and five and 10 minutes later. The lowest reading was taken as the baseline value. They then inhaled the concentration of D pteronyssinus antigen in albumin, which produced a 3 mm weal when pricked into the skin, and measurements were repeated as before. Doubling concentrations of antigen were used and the procedure was repeated until a greater than 20% fall in FEVJ was sustained 20 minutes after the end of nebulisation. This final concentration of antigen was then used to induce bronchoconstriction on the study day, which was between one and two weeks after the first antigen challenge. On the study day the subject inhaled first albumin and then 10 minutes later the previously determined antigen concentration. Measurements of FEV, and PEFR were continued at five minute intervals for a further 20 minutes. At (b) On visual inspection, "In platelet survival was linear. For comparison of individuals, "'In activity in each blood sample was expressed as a percentage of the one hour value in each subject. All the data were then pooled and linear regression by the method of least squares was performed to give the mean platelet lifespan for asthmatic and normal subjects.
(c) Intrapulmonary platelet traffic was quantified in two ways. Firstly, the lung platelet population was measured by continuously recording the "'In signal with a gamma camera from a region of interest over the lungs. Secondly, the ratio of platelet to red cell transit time through the lung was measured. This ratio would be unity if there was no platelet accumulation relative to red cells in the lung but would rise above unity if platelets "pooled" outside the circulating blood volume (as marked by 99mTc red cells). A difference between the transit times of platelets and red cells would be reflected by different lung signals given by "'In and 99mTc relative to their corresponding peripheral blood levels. The ratio of these transit times can therefore be calculated from the equation 
Results
RECOVERY AND LIFESPAN
Recovery of "'In platelets after equilibration was the same in asthmatic and normal subjects (table 2). Platelet lifespan also did not differ in the two groups, being 10.2 days in both (fig 1) .
TRANSPULMONARY PLATELET-RED CELL TRANSIT
There was a slight tendency for higher transit ratios in asthmatic than in normal subjects, though the values overlapped (table 2). The responses of the "'In platelet and 99mTc red cell pulmonary signals to antigen challenge are shown in figure 2 . Antigen challenge resulted in a slight but significant (p < 0.001) fall in the "'In signal in each subject, indicating a fall in platelet numbers in the region of lung monitored by the camera. The percentage decrease ranged from 6% to 11%. The lung red cell signal did not decrease in subjects I and 2; there were insufficient data on subject 3. The ratio of platelet to red cell transit times also showed a tendency to fall after bronchial provocation (table 2) .
Discussion
IgE dependent release of mediators from mast cells is thought to be central to immediate hypersensitivity reactions, including allergic asthma. The possible role of other cell types should not be neglected. The part played by platelets in asthma is largely unexplored, yet there is considerable evidence linking platelets and bronchoconstriction in animals. Firstly, platelets are a potential source of bronchoconstrictor mediators. Platelets from asthmatic subjects release more lipoxygenase and less cyclooxygenase products from exogenous arachidonic acid than from control platelets and this imbalance is restored by steroids.'7 Secondly, platelet activating factor (PAF) is a potent constrictor mediator pro-FEV, (% change) The present study reports data on pulmonary platelet kinetics in normal and asthmatic subjects. It has been suggested that platelets are normally concentrated relative to red cells in the pulmonary vasculature;24 25 but we found the ratio of platelet to red cell transit time to be almost unity (table 2) , which argues against the existence of a pulmonary platelet pool. Furthermore, we have shown that, although this ratio may be slightly increased in asthmatic subjects at rest (table 2) , it does not increase with antigen induced bronchoconstriction. Indeed, small decreases in the camera detected pulmonary platelet signal were found after antigen challenge, indicating a reduced pulmonary platelet population. Applying the same statistical approach to the corresponding red cell signal in two of the three asthmatic subjects, we can be 99% confident that the red cell signal did not decrease by more than 5%. This excludes an increase in platelet-red cell transit time as a consequence of a fall in red cell transit time and is in line with the determination of transit time ratio based on blood sampling. We have therefore found no evidence, by either of our two measurements, of platelet accumulation in the lung in the early bronchoconstrictor response to inhaled antigen. Although this contrasts with the reversible intrapulmonary accumulation of platelets that accompanies ovalbumin challenge of sensitised guineapigs,'2 the animal model differs from human asthma in the route of antigen administration, and there are appreciable differences in immunoglobulin response and in mediator production and responsiveness in the two species.
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The possibility that these labelled platelets failed to respond because of damage inflicted during the labelling procedure is not supported by the normal recovery and lifespan2927 that they displayed. They were labelled in their physiological medium plasma, which has been shown to promote viability for both platelets28 and leucocytes.29 They also displayed normal splenic pooling kinetics27 and underwent negligible initial hepatic uptake, the occurrence of which is associated with labelling induced injury."' Finally, "I'In labelled platelets are clearly capable of aggregating in vivo in man. Gamma camera imaging is able to detect platelet uptake in renal allograft rejection,3' on the surface of prosthetic arterial grafts,32 in peripheral vascular disease,33 and in deep venous thrombosis. 34 The theoretical sensitivity of our technique in detecting changes in lung platelet population can be estimated from the standard deviation of the count rate before antigen challenge. We calculate that 3.4%, 3.5%, and 5.4% changes in platelet signal could be detected with a level of confidence of 99%. In fact, significant reductions in platelet signal were found.
These data indicate that if platelets do play a part in the early phase of antigen induced bronchoconstriction in asthma they do so without accumulating in the lung. This conclusion is supported by the finding of a normal platelet lifespan in these asthmatic subjects. This work was supported by a programme grant from the Medical Research Council.
